Trial Profile
A Single-Institute Study Investigating Apatinib for Pulmonary Metastases in Hepatocellular Carcinoma (HCC) Patients following Transcatheter Arterial Chemoembolization (TACE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Jun 2018 New trial record
- 05 Jun 2018 Results (data cut-off date: 21 Nov 2017) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.